Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.45862 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Calvin Trieu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Biomarkers. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Blood-based biomarkers identify Alzheimer disease and hold promise for monitoring disease progression, even in the preclinical disease stages.
Objective
To investigate longitudinal trajectories of blood-based biomarkers and association with cognitive decline and risk of progression in individuals with subjective cognitive decline (SCD). Design, Setting, and Participants This prospective cohort study (Subjective Cognitive Impairment Cohort) of individuals with SCD evaluated at a memory clinic underwent biennial biomarker collection and annual cognitive assessment and diagnostic evaluation from January 1, 2005, to December 31, 2023, with follow-up through 2023. Exposure Amyloid status was determined using positron emission tomography or cerebrospinal fluid. Plasma Aβ 42/40 , phosphorylated tau 217 (pTau217), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) were measured biennially. Main Outcomes and Measures Cognitive trajectories in memory, attention, language, executive function, and global cognition and clinical progression to mild cognitive impairment or dementia.
Results
A total of 298 individuals (mean [SD] age, 61.55 [8.08] years; 174 [58.4%] male) with SCD were included, of whom 80 were amyloid-positive (A+) and 218 were amyloid-negative (A−). Mean (SD) follow-up was 4.8 (2.6) years. Individuals with SCD A+ were older (mean [SD] age, 65.25 [7.14] years; 42 [52.5%] male) than those with SCD A− (mean [SD] age, 60.19 [8.00] years; 132 [60.6%] male). For pTau217, GFAP, and NfL, baseline levels were higher in the A+ group compared with A− group (estimates [SE] amyloid β, 1.11 [0.11], 0.69 [0.13], and 0.36 [0.10], respectively; P < .001 for all). Additionally, these biomarkers showed steeper increases over time in the A+ group than in A− group (estimates [SE] time × amyloid status β, 0.07 [0.02], P < .001; 0.07 [0.02], P < .001; and 0.05 [0.02], P = .005, respectively). Longitudinal increases in pTau217 and GFAP were associated with cognitive decline over time in all domains (β time × biomarker slope = −0.02 to −0.04). Longitudinal decreases in Aβ 42/40 and increases in NfL were associated with cognitive decline in global cognition (β = 0.03 [0.01], P = .04) and language (β = 0.04 [0.02], P = .03), and increases in NfL were also associated with decline in global cognition (β = −0.02 [0.01], P = .004), language (β = −0.03 [0.01], P = .007), and executive functioning (β = −0.03 [0.01], P = .02). Steeper pTau217 slope was associated with progression from SCD to mild cognitive impairment or dementia (hazard ratio [HR], 3.6; 95% CI, 1.8-7.4 per 0.05 SD increase per year; C index, 0.89; 95% CI, 0.84-0.93), as were steeper GFAP slope (HR, 1.5 [95% CI, 1.0-2.2]; C index, 0.81 [95% CI, 0.73-0.88]) and steeper NfL slope (HR, 2.6 [95% CI, 1.3-5.2]; C index, 0.77 [95% CI, 0.69-0.85]). Aβ 42/40 slope was not associated with progression. Conclusions and Relevance This cohort study of individuals with SCD suggests that longitudinal plasma pTau217 and GFAP are suitable biomarkers for monitoring AD pathology. Their changes were associated with cognitive decline and clinical progression, supporting their potential utility for early intervention and disease monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam, Netherlands.
- Faculty of Behavioural and Movement Sciences, Department of Clinical, Neuro and Developmental Psychology & Clinical Neuropsychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Zitieren
APA
Trieu, C., van Harten, A. C., van Leeuwenstijn, M. S. S. A., Schlüter, L. M., Boonkamp, L., Aladdin, A., Sikkes, S. A. M., van de Giessen, E., Verberk, I. M. W., Teunissen, C. E., & van der Flier, W. M. (2025). Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.45862
Vancouver
Trieu C, van Harten AC, van Leeuwenstijn MSSA, Schlüter LM, Boonkamp L, Aladdin A, et al. Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.45862
BibTeX
@article{Trieu2025,
author = {Trieu, Calvin and van Harten, Argonde C and van Leeuwenstijn, Mardou S S A and Schlüter, Lisa-Marie and Boonkamp, Lynn and Aladdin, Azzam and Sikkes, Sietske A M and van de Giessen, Elsmarieke and Verberk, Inge M W and Teunissen, Charlotte E and van der Flier, Wiesje M},
title = {Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.45862}
}
EUVIMED